Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia

Andrica C H de Vries; Ronald W Stam; Pauline Schneider; Charlotte M Niemeyer; Elisabeth R van Wering; Oskar A Haas; Christian P Kratz; Monique L den Boer; Rob Pieters; Marry M van den Heuvel-Eibrink

doi:10.3324/haematol.11201

Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia

Andrica C H de Vries, Ronald W Stam, Pauline Schneider, Charlotte M Niemeyer, Elisabeth R van Wering, Oskar A Haas, Christian P Kratz, Monique L den Boer, Rob Pieters, Marry M van den Heuvel-Eibrink

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

10 Citaten (Scopus)

Samenvatting

FLT3 gene mutations have been identified as prognostic factors in myeloid malignancies. Furthermore, FLT3 can be activated by wild type overexpression or ligand-dependent in leukemic cells co-expressing FLT3 ligand (FLT3L). So far no data are available on FLT3/FLT3L expression and activation in JMML. In 51 clinical JMML samples, activating mutations were screened, FLT3 and FLT3L mRNA levels were assessed and the sensitivity of JMML cells to the FLT3 inhibitor PKC412 was tested by MTT assays. No evidence for constitutively activation of FLT3/FLT3L was found in JMML, indicating that FLT3 inhibitors are unlikely to be effective in JMML.

Originele taal-2	Engels
Pagina's (van-tot)	1557-60
Aantal pagina's	4
Tijdschrift	Haematologica
Volume	92
Nummer van het tijdschrift	11
DOI's	https://doi.org/10.3324/haematol.11201
Status	Gepubliceerd - nov. 2007
Extern gepubliceerd	Ja

Toegang tot document

10.3324/haematol.11201

Citeer dit

@article{d0981a29aab2483a807efa22b572540b,

title = "Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia",

abstract = "FLT3 gene mutations have been identified as prognostic factors in myeloid malignancies. Furthermore, FLT3 can be activated by wild type overexpression or ligand-dependent in leukemic cells co-expressing FLT3 ligand (FLT3L). So far no data are available on FLT3/FLT3L expression and activation in JMML. In 51 clinical JMML samples, activating mutations were screened, FLT3 and FLT3L mRNA levels were assessed and the sensitivity of JMML cells to the FLT3 inhibitor PKC412 was tested by MTT assays. No evidence for constitutively activation of FLT3/FLT3L was found in JMML, indicating that FLT3 inhibitors are unlikely to be effective in JMML.",

keywords = "Enzyme Activation, Enzyme Inhibitors/pharmacology, Humans, Leukemia, Myelomonocytic, Juvenile/enzymology, RNA, Messenger/analysis, Staurosporine/analogs & derivatives, fms-Like Tyrosine Kinase 3/antagonists & inhibitors",

author = "{de Vries}, {Andrica C H} and Stam, {Ronald W} and Pauline Schneider and Niemeyer, {Charlotte M} and {van Wering}, {Elisabeth R} and Haas, {Oskar A} and Kratz, {Christian P} and {den Boer}, {Monique L} and Rob Pieters and {van den Heuvel-Eibrink}, {Marry M}",

year = "2007",

month = nov,

doi = "10.3324/haematol.11201",

language = "English",

volume = "92",

pages = "1557--60",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "11",

}

TY - JOUR

T1 - Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia

AU - de Vries, Andrica C H

AU - Stam, Ronald W

AU - Schneider, Pauline

AU - Niemeyer, Charlotte M

AU - van Wering, Elisabeth R

AU - Haas, Oskar A

AU - Kratz, Christian P

AU - den Boer, Monique L

AU - Pieters, Rob

AU - van den Heuvel-Eibrink, Marry M

PY - 2007/11

Y1 - 2007/11

N2 - FLT3 gene mutations have been identified as prognostic factors in myeloid malignancies. Furthermore, FLT3 can be activated by wild type overexpression or ligand-dependent in leukemic cells co-expressing FLT3 ligand (FLT3L). So far no data are available on FLT3/FLT3L expression and activation in JMML. In 51 clinical JMML samples, activating mutations were screened, FLT3 and FLT3L mRNA levels were assessed and the sensitivity of JMML cells to the FLT3 inhibitor PKC412 was tested by MTT assays. No evidence for constitutively activation of FLT3/FLT3L was found in JMML, indicating that FLT3 inhibitors are unlikely to be effective in JMML.

AB - FLT3 gene mutations have been identified as prognostic factors in myeloid malignancies. Furthermore, FLT3 can be activated by wild type overexpression or ligand-dependent in leukemic cells co-expressing FLT3 ligand (FLT3L). So far no data are available on FLT3/FLT3L expression and activation in JMML. In 51 clinical JMML samples, activating mutations were screened, FLT3 and FLT3L mRNA levels were assessed and the sensitivity of JMML cells to the FLT3 inhibitor PKC412 was tested by MTT assays. No evidence for constitutively activation of FLT3/FLT3L was found in JMML, indicating that FLT3 inhibitors are unlikely to be effective in JMML.

KW - Enzyme Activation

KW - Enzyme Inhibitors/pharmacology

KW - Humans

KW - Leukemia, Myelomonocytic, Juvenile/enzymology

KW - RNA, Messenger/analysis

KW - Staurosporine/analogs & derivatives

KW - fms-Like Tyrosine Kinase 3/antagonists & inhibitors

U2 - 10.3324/haematol.11201

DO - 10.3324/haematol.11201

M3 - Article

C2 - 18024405

SN - 0390-6078

VL - 92

SP - 1557

EP - 1560

JO - Haematologica

JF - Haematologica

IS - 11

ER -

Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit